Creative Touch Permanent Makeup and Aesthetics

Butyric acid is a four-carbon short-chain fatty acid, existing in its ionised form as butyrate at physiological pH, produced in the large intestine by commensal bacterial fermentation of dietary substrates, and delivered directly from ruminant dairy fat as tributyrin. It serves as the primary energy source for colonocytes, fuelling the gut epithelial cells that maintain the barrier between gut contents and systemic circulation. As the most potent HDAC inhibitor among the SCFAs, butyrate also functions as an epigenetic regulator – promoting regulatory T-cell differentiation, suppressing pro-inflammatory macrophage activity, and driving the correct terminal differentiation of keratinocytes in the epidermis. Its name traces directly to the substance in which it was first identified: butyrum, the Latin for butter.

A Name Written in Butter

The word butyrate carries its own history. The English words butter and butyric acid share a root: Old English butere derived from Latin butyrum, which itself came from the Greek boutyron – a compound of bous (ox) and tyros (cheese), reflecting the dairy origins of the substance. It was the French chemist Michel Eugène Chevreul who first characterised the compound responsible for the smell of butter and rancid dairy in the early 19th century, publishing his findings on its properties between 1817 and 1823 and naming it butyric acid after the substance in which it was found. The line from his discovery to the gut microbiome research of the past two decades is as direct as the etymology: butter is still one of the most concentrated dietary sources of preformed butyrate, and the biological significance of the compound Chevreul isolated from dairy turns out to extend far beyond its smell.

Butyrate exists in two forms. Butyric acid (C₄H₈O₂) is the free acid form; butyrate is its ionised salt or ester form, which predominates at physiological pH. In the body, the terms are used interchangeably in most contexts. In ruminant dairy fat, it is esterified as tributyrin – a triglyceride in which three butyrate molecules are bound to a glycerol backbone – released as free butyrate by pancreatic lipases during digestion. ^[4]

Butyrate as Colonocyte Fuel

Butyrate’s most established role is as the preferred energy substrate for colonocytes – the epithelial cells lining the large intestine. Unlike most cells in the body, which rely primarily on glucose for energy, colonocytes preferentially oxidise butyrate via mitochondrial β-oxidation, obtaining approximately 60–70% of their energy from this source. This preference is not incidental – it reflects a co-evolutionary relationship between the colonic epithelium and the microbial community that produces butyrate as a fermentation output. ^[6]

The practical consequence of this dependency is that colonocyte metabolic function is directly coupled to SCFA production by gut bacteria. When dysbiosis reduces the abundance of butyrate-producing species – principally Faecalibacterium prausnitzii and Roseburia – the colonocyte energy supply falls, mitochondrial respiration becomes less efficient, and the cells that maintain the epithelial barrier begin to function below optimal capacity. The anaerobic environment of the colon, which is itself maintained partly by efficient colonocyte oxygen consumption, also becomes less stable – a detail that matters because the low-oxygen environment is what preferentially supports commensal bacteria over facultative anaerobes. Butyrate depletion therefore risks destabilising the ecological conditions that favour the bacteria responsible for producing it. ^[3]

Butyrate and Gut Barrier Integrity

Beyond colonocyte fuel, butyrate acts directly on the tight junction network that controls paracellular permeability – the gaps between epithelial cells through which molecules can pass when barrier integrity is compromised.

The primary mechanism is AMPK activation. Research using Caco-2 cell monolayer models demonstrated that butyrate at physiological concentrations activates AMPK (AMP-activated protein kinase), accelerating the assembly of tight junction proteins ZO-1 and occludin at cell junctions and measurably increasing transepithelial electrical resistance (TEER). Blocking AMPK with compound C fully abolished the butyrate-induced barrier improvement, confirming AMPK as the operative pathway. Under inflammatory challenge, butyrate additionally protects claudin-3 and claudin-4 expression against LPS-induced downregulation – a protective effect on the tight junction proteins most vulnerable to inflammatory damage. ^[7]

Butyrate also drives mucin gene expression in intestinal goblet cells. When butyrate is the primary available substrate, MUC2 and MUC5B expression increases substantially, thickening the protective mucus layer above the epithelium – the first physical barrier between the gut lumen and the epithelial surface. The gut barrier butyrate supports is therefore two layers deep: the tight junction seal between epithelial cells, and the mucus architecture above them. ^[5]

Butyrate as an Epigenetic Regulator – HDAC Inhibition

Butyrate’s second major mechanism of action operates at the level of gene expression. It is a histone deacetylase (HDAC) inhibitor – meaning it prevents HDACs from removing acetyl groups from histone proteins, keeping chromatin in a more open, transcriptionally accessible state. Of the three principal SCFAs, butyrate is the most potent HDAC inhibitor by a significant margin: IC₅₀ values of approximately 1.13 mM for butyrate versus approximately 10 mM for propionate, and greater than 10 mM for acetate – roughly a 10-fold differential. ^[2]

The immunological consequence is a shift toward tolerance. Butyrate-driven HDAC inhibition promotes the expression of Foxp3, the transcription factor required for regulatory T-cell (Treg) differentiation, by maintaining chromatin accessibility at the Foxp3 locus. A PNAS study confirmed that butyrate enhances CPT1A (carnitine palmitoyltransferase 1A) activity, promoting the fatty acid oxidation that fuels iTreg differentiation – a metabolic mechanism distinct from the Foxp3 epigenetic route and operating in parallel with it. IL-4, the type 2 inflammatory cytokine that drives atopic conditions and suppresses filaggrin expression, specifically inhibits Treg differentiation through HDAC9-mediated epigenetic suppression of Foxp3; sodium butyrate as a pan-HDAC inhibitor reverses this effect and restores Treg proportions in experimental models. This is mechanistically significant: the same inflammatory cytokine environment that suppresses filaggrin in the epidermis also suppresses the Treg populations that butyrate helps maintain – and butyrate counters both suppressions through the same HDAC inhibition pathway. ^[1]

Clinical Pearl The IL-4 → HDAC9 → Foxp3 suppression → fewer Tregs pathway is the same inflammatory environment that drives acquired filaggrin deficiency in reactive skin. Butyrate’s ability to restore Treg populations via pan-HDAC inhibition means it operates on the upstream immune environment that maintains both gut barrier tolerance and epidermal barrier competency – not simply as a gut metabolite but as a systemic immunological regulator.

Butyrate and the Skin

The butyrate-to-skin connection operates through both systemic immune effects and more direct keratinocyte pathways.

Systemically, adequate butyrate production reduces the IL-4/ IL-13 and pro-inflammatory cytokine burden that, when elevated, suppresses filaggrin expression and impairs ceramide synthesis via STAT6-mediated ELOVL and SPT inhibition. This is the indirect route – gut-derived immune regulation reducing the systemic inflammatory environment that limits epidermal barrier repair. The direct route is more recently characterised: butyrate enhances filaggrin and transglutaminase-1 expression in normal human epidermal keratinocytes through HDAC inhibition, promoting the terminal differentiation programme that produces a structurally competent corneocyte. Butyrate is also metabolised by keratinocytes in a way that enhances synthesis of long-chain fatty acids (LCFAs) and very-long-chain fatty acids (VLCFAs) – the substrates required for ceramide production. ^[8]

These direct keratinocyte effects establish butyrate as operating on skin barrier function through mechanisms that are genuinely additive to topical and professional treatment approaches rather than overlapping with them. Topical ceramides and phytoceramides supply the barrier directly; SCFA-driven keratinocyte LCFA synthesis supports the skin’s own capacity to produce them.

Sources of Butyrate

Microbial production is the primary route – Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale, and Butyrivibrio fibrisolvens are the principal butyrate-producing bacteria in the human colon, fermented from indigestible dietary substrates. Resistant starch – found in cooled cooked potatoes, green bananas, and legumes – is a particularly effective butyrate-production substrate for these species.

Pre-formed tributyrin in ruminant dairy – butter, cream, and aged cheese contain butyrate esterified as tributyrin, released by pancreatic lipases and delivered to the colon without requiring microbial fermentation. This is the route that gives butyrate its name and its most historically consistent dietary source.

Fermented dairy – kefir, natural yoghurt, and some aged cheeses deliver both live butyrate-producing organisms and short-chain organic acids generated during fermentation, supporting microbial production capacity directly.